研究方向：
致力于免疫治疗及个性化疫苗体系设计、制备及功能评价，基于仿生学的功能化靶向递送系统构建，及基于表观遗传学的工程疫苗载体改造。研究内容主要包括：
（1）新型功能化抗肿瘤/感染疫苗设计；
（2）免疫共刺激信号递送平台；
（3）T细胞免疫耐受诱导与逆转及肿瘤微环境调控。
科研成果：
设计工程化细胞衍生的功能疫苗平台用于肿瘤、病毒感染、寄生虫感染、神经退行性疾病、自身免疫性疾病等免疫治疗，系统地研究了抗原递呈及免疫识别之间的相关性及其规律，探索了分子影像探针对疫苗载体的标记技术方法，建立了系统的疫苗免疫学机制挖掘与疗效评价体系。发表SCI论文50余篇，其中以第一或通讯作者（含共同）在Nature Nanotechnology、Nature Communications、Science Advances、Gut、Angewandte Chemie等国际高水平期刊上发表论文34篇，论文篇均影响因子超过15分，并已向科技公司转让相关重要发明专利数项，受邀担任Military Medical Research、Exploration、 Materials Today Bio等杂志编委。
主持国家自然科学基金面上项目、福建省“雏鹰计划青年拔尖人才”项目、省杰青项目，及其它省市级科学基金共11项，累计到位主持项目经费700余万元。
代表论著：
(*: corresponding author; #: equal contribution)
(1) Chao Liu#, Xue Liu#, Xinchu Xiang, Xin Pang, Siyuan Chen, Yunming Zhang, En Ren, Lili Zhang, Xuan Liu, Peng Lv, Xiaoyong Wang, Wenxin Luo, Ningshao Xia, Xiaoyuan Chen*, Gang Liu*. A Nanovaccine for Antigen Self-presentation and Immunosuppression Reversal as a Personalized Cancer Immunotherapy Strategy. Nature Nanotechnology, 2022, 17, 531-540. （IF=37.5）
News&Views: Yahya Mohammadzadeh, Michele De Palma*. Boosting dendritic cell nanovaccines. Nature Nanotechnology, 2022, 17, 442-444.
(2) Qianwen Mu#, Haolan Deng#, Shuo Li#, Xiaoyu An, Xuan Liu, Yue Xi, Hao Liang, Di Sun, Xiaojun Wang, Xue Liu, Gang Liu*, Chao Liu*. A biomimetic nanodisc system selectively activates type I interferons by nonclassical STING pathway for cancer immunotherapy. Nature Communications, 2026, DOI:10.1038/s41467-026-71363-6. （IF=18.1）
(3) Shuo Li#, Peiyu Wang#, Zhenyu Wu#, Qianwen Mu#, Renwu Zhou#, Nina Liu, Yue Xi, Xiaoyu An, Yan Li, Di Sun, Hao Liang, Chenhao Zhang, Qihang Huang, Ziqi Zhuang, Xiaojun Wang, Liqian Zhao, Dingwei Gan, Xiaoyong Wang, Xue Liu, Gang Liu*, Chao Liu*. Cold Atmospheric Plasma Engineered Nanovaccine with Spatiotemporal Sequential Immunization Reprograms Antitumor Immunity. Science Advances, 2026, 12(13):eaeb5894. （IF=13.9）
(4) Xiaoqing Chen, Xue Liu *, Tao Xu, Yalin Wang, Peng Wang, Han Liu, Yichao Jiang, Xiaojing Qin, Liang Zhang, Yueting Xiong, Jiancheng Ding, Yuanzhi Chen, Fentian Chen, Wenjing Ning, Hongye Zeng, Shiting Yang, Lin Xu, Tianying Zhang, Quan Yuan, Chao Liu*, Wenxin Luo*, Ningshao Xia*. Engineered virus-hunter vaccine overcomes HBV immune tolerance. Gut. 2025, gutjnl-2025-335806. （IF=24.6）
(5) Xue Liu#, Chao Liu#, Zizheng Zheng#, Siyuan Chen, Xin Pang, Xinchu Xiang, Jixian Tang, En Ren, Yuanzhi Chen, Min You, Xiaoyong Wang, Xiaoyuan Chen, Wenxin Luo*, Gang Liu*, Ningshao Xia*. Vesicular Antibodies: A bioactive multifunctional combination platform for targeted therapeutic delivery and cancer immunotherapy, Advanced Materials. 2019, 31(17), e1808294. （IF=29.1）
(6) Xiaoyu An#, Wei Xiang#, Xue Liu#, Shuo Li, Zhijian Xu, Pan He, Ri-Li Ge, Feng Tang*, Zhe Cheng*, Chao Liu*, Gang Liu*. A Bioengineered Nanovesicles Vaccine Boosts T-B cell Interaction for Immunotherapy of Echinococcus multilocularis. Angewandte Chemie International Edition. 2024, 63(13) e202319489. （IF=17.6）
(7) Chaojie Zhu#, Chao Liu#, Qing Wu, Tao Sheng, Ruyi Zhou, En Ren, Ruizhe Zhang, Zhengjie Zhao, Jiaqi Shi, Xinyuan Shen, Zhongquan Sun, Zhengwei Mao, Kaixin He, Lingxiao Zhang, Yuan Ding*, Zhen Gu*, Weilin Wang*, Hongjun Li*. Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors. Signal Transduction and Targeted Therapy. 2024, 9(1):307. （IF=81.2）
本实验室诚招博士后，博士及硕士研究生（长期有效）。
